SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Anatomic Stage IV Breast Cancer AJCC v8|Breast Inflammatory Carcinoma|Metastatic Triple-Negative Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8
Interventions: DRUG: Carboplatin|BIOLOGICAL: Pembrolizumab|GENETIC: Transferrin Receptor-Targeted Liposomal p53 cDNA
Sponsor: Northwestern University
Collaborators: National Cancer Institute (NCI)